Sandra Colner, Global Head of Labs and Life Sciences Vertical, Intel; Paul Dobson, Head of Data, ValitaCell
The biopharmaceutical industry is undergoing a digital transformation with AI at the forefront, driving innovation and enhancing business models. AI has the potential to enable the analysis of massive databases, accelerate research and redevelopment, save costs, and promote effective decision making.
ValitaCell aims to transform how life-saving biological medicines are manufactured – the right data can help streamline biologics production and unlock enormous potential for cell therapies. ValitaCell’s AI tools provide efficient data streams to spark a bioprocessing revolution. Their CellAI portfolio of AI algorithms helps extract rich cell insights from simple images to steer bioprocess design and operation.
In this virtual fireside chat, Intel’s Sandi Colner, global head of labs and life sciences vertical, and ValitaCell’s Paul Dobson, head of data, discuss how the two companies are collaborating on a cutting-edge AI project for cell imaging, address some of the challenges facing the biopharma industry and preview what’s next.